Cai Jing Wang·2025-08-18 13:15Core Viewpoint - Baiyunshan's semi-annual performance report indicates a slight increase in revenue but a decline in profits, attributed to insufficient demand, intensified industry competition, and ongoing policy impacts [1] Financial Performance - The group achieved operating revenue of 41.835 billion yuan, representing a year-on-year increase of 1.93% [1] - Total profit amounted to 3.09 billion yuan, showing a year-on-year decrease of 4.30% [1] - Net profit attributable to shareholders was 2.516 billion yuan, reflecting a year-on-year decline of 1.31% [1] Product Performance - Revenue from traditional Chinese medicine reached 3.246 billion yuan, down 20.12% year-on-year [1] - Chemical medicine revenue was 1.994 billion yuan, a decrease of 5.85% year-on-year [1] - Total revenue from Daan Pharmaceutical was 5.241 billion yuan, down 15.23% year-on-year [1]